NO20093488L - Biomarkorer for a predikere anti-TNF respons eller ikke-respons - Google Patents

Biomarkorer for a predikere anti-TNF respons eller ikke-respons

Info

Publication number
NO20093488L
NO20093488L NO20093488A NO20093488A NO20093488L NO 20093488 L NO20093488 L NO 20093488L NO 20093488 A NO20093488 A NO 20093488A NO 20093488 A NO20093488 A NO 20093488A NO 20093488 L NO20093488 L NO 20093488L
Authority
NO
Norway
Prior art keywords
response
tnf
biomarkers
predicting anti
person
Prior art date
Application number
NO20093488A
Other languages
English (en)
Norwegian (no)
Inventor
Jadwiga Bienkowska
John P Carulli
Peter K Gregersen
Franak Batliwalla
Chunyu Liu
Original Assignee
The Feinstein Inst Medical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Feinstein Inst Medical Res filed Critical The Feinstein Inst Medical Res
Publication of NO20093488L publication Critical patent/NO20093488L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
NO20093488A 2007-06-08 2009-12-08 Biomarkorer for a predikere anti-TNF respons eller ikke-respons NO20093488L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94293707P 2007-06-08 2007-06-08
PCT/US2008/066180 WO2008154423A2 (en) 2007-06-08 2008-06-06 Biomarkers for predicting anti-tnf responsiveness or non-responsiveness

Publications (1)

Publication Number Publication Date
NO20093488L true NO20093488L (no) 2010-01-08

Family

ID=40130456

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20093488A NO20093488L (no) 2007-06-08 2009-12-08 Biomarkorer for a predikere anti-TNF respons eller ikke-respons

Country Status (16)

Country Link
US (1) US20100303813A1 (https=)
EP (2) EP2617837A3 (https=)
JP (2) JP5719591B2 (https=)
KR (1) KR20100037590A (https=)
CN (2) CN101796197B (https=)
AU (1) AU2008261869B2 (https=)
BR (1) BRPI0812461A2 (https=)
CA (1) CA2690898A1 (https=)
EA (1) EA017815B1 (https=)
IL (2) IL202562A0 (https=)
MX (1) MX2009013410A (https=)
NO (1) NO20093488L (https=)
NZ (1) NZ581742A (https=)
SG (1) SG182183A1 (https=)
WO (1) WO2008154423A2 (https=)
ZA (1) ZA200909215B (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090235713A1 (en) * 2008-03-24 2009-09-24 Hirotec America, Inc. Magnetically actuated roller head
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US8512964B2 (en) 2008-12-12 2013-08-20 The Regents Of The University Of California Targets for treatment of hypercholesterolemia
JP4883117B2 (ja) * 2009-03-23 2012-02-22 コニカミノルタビジネステクノロジーズ株式会社 画像処理装置の課金装置、それを用いた画像処理装置、画像処理装置の課金装置の制御方法、及び画像処理装置の課金装置の制御プログラム
EP3360978A3 (en) 2009-05-07 2018-09-26 Veracyte, Inc. Methods for diagnosis of thyroid conditions
JP5996429B2 (ja) 2009-09-03 2016-09-21 ジェネンテック， インコーポレイテッド 関節リウマチの治療、診断及びモニターするための方法
EP3409289B1 (en) 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
CN102918165A (zh) * 2010-03-24 2013-02-06 Tc园表达公司 患有炎症疾病的受试者对细胞因子靶向药物（CyTD）的早期反应或无反应预测的基因和基因组合
RU2012153786A (ru) 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
MX353143B (es) 2011-02-28 2017-12-20 Genentech Inc Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b.
WO2013117751A2 (en) 2012-02-10 2013-08-15 Novo Nordisk A/S Methods related to treatment of inflammatory diseases and disorders
US9031292B2 (en) * 2012-04-19 2015-05-12 Chang Gung University Method for the diagnosis of neurodegenerative disorder by using diffusion kurtosis imaging
EP2861767A4 (en) * 2012-06-15 2016-07-27 Nuclea Biotechnologies Inc PREDICTIVE MARKERS FOR CANCER AND METAL CHANGE SYNDROME
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
ES2524164B1 (es) * 2013-05-03 2015-10-27 Fundació Hospital Universitari Vall D'hebron - Institut De Recerca Pronóstico de respuesta al tratamiento con anti-tnfalfa en pacientes de artritis reumatoide
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
WO2016040861A1 (en) * 2014-09-12 2016-03-17 Biogen Ma Inc. Systems and methods for characterization of multiple sclerosis
US20170335396A1 (en) 2014-11-05 2017-11-23 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
US10098168B2 (en) * 2014-12-08 2018-10-09 Apple Inc. Neighbor awareness networking datapath
GB2547406A (en) * 2015-11-20 2017-08-23 Folkersen Lasse Apparatus and methods of using of biomarkers for predicting TNF-inhibitor response
GB201521357D0 (en) * 2015-12-03 2016-01-20 Univ Liverpool Methods for predicting response to anti-TNF therapy
WO2017096031A1 (en) * 2015-12-03 2017-06-08 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf
CN106520771B (zh) * 2016-12-20 2019-02-12 江苏省人民医院 一种长非编码rna及其在诊断/治疗子痫前期中的应用
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
KR102094802B1 (ko) * 2017-10-24 2020-03-31 고려대학교 산학협력단 소변 대사체 분석을 이용한 베체트병의 진단방법
JP7496324B2 (ja) * 2018-03-16 2024-06-06 サイファー メディシン コーポレイション 抗ｔｎｆ療法に対する応答性を予測するための方法及びシステム
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN110141578B (zh) * 2019-06-10 2022-06-14 南通大学 环状RNA circ-Ankib1在制备促进神经再生和修复神经损伤药物中的应用
GB2603294A (en) 2019-06-27 2022-08-03 Scipher Medicine Corp Developing classifiers for stratifying patients
KR20240018404A (ko) * 2020-09-01 2024-02-13 사이퍼 메디슨 코퍼레이션 항-tnf 요법에 대한 반응을 예측하기 위한 방법 및 시스템
US12379368B2 (en) * 2020-09-11 2025-08-05 Washington University Methods for determining therapeutic responsiveness for inflammatory bowel disease therapy
CN112180082B (zh) * 2020-09-27 2022-03-08 西安交通大学 Tweak在制备红斑狼疮诊断试剂中的应用
RU2749247C1 (ru) * 2020-09-28 2021-06-07 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) (ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Се Способ прогнозирования эффективности лечения ревматоидного артрита препаратом олокизумаб на основе генотипирования

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499052A (en) 1982-08-30 1985-02-12 Becton, Dickinson And Company Apparatus for distinguishing multiple subpopulations of cells
US4582789A (en) 1984-03-21 1986-04-15 Cetus Corporation Process for labeling nucleic acids using psoralen derivatives
US4563417A (en) 1984-08-31 1986-01-07 Miles Laboratories, Inc. Nucleic acid hybridization assay employing antibodies to intercalation complexes
SE458968B (sv) 1987-06-16 1989-05-22 Wallac Oy Biospecifikt analysfoerfarande foer flera analyter i vilket ingaar partikelraekning och maerkning med fluorescerande maerksubstanser
DK641487A (da) 1987-12-07 1989-06-08 Gluetech Aps Fremgangsmaade til modificering af polymeroverflader
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5871928A (en) 1989-06-07 1999-02-16 Fodor; Stephen P. A. Methods for nucleic acid analysis
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
EP0834575B1 (en) 1990-12-06 2001-11-28 Affymetrix, Inc. (a Delaware Corporation) Identification of nucleic acids in samples
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
US6027880A (en) 1995-08-02 2000-02-22 Affymetrix, Inc. Arrays of nucleic acid probes and methods of using the same for detecting cystic fibrosis
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
FR2707882B1 (fr) 1993-07-23 1997-08-01 Immunotech Sa Nouveaux kits thérapeutiques anti-médiateurs protéiques, procédé de préparation et compositions pharmaceutiques les renfermant.
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
US8017121B2 (en) 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US5981180A (en) 1995-10-11 1999-11-09 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and methods
US6057100A (en) 1996-06-07 2000-05-02 Eos Biotechnology, Inc. Oligonucleotide arrays
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
US6197599B1 (en) 1998-07-30 2001-03-06 Guorong Chin Method to detect proteins
US7473528B2 (en) * 1999-01-06 2009-01-06 Genenews Inc. Method for the detection of Chagas disease related gene transcripts in blood
US6410231B1 (en) 1999-02-26 2002-06-25 Incyte Genomics, Inc. SNP detection
EP1204869B1 (en) 1999-08-17 2008-10-22 Luminex Corporation Method for analyzing a number of samples from a variety of sources for a single analyte
AU783841B2 (en) 1999-11-26 2005-12-15 454 Life Sciences Corporation Nucleic acid probe arrays
WO2001074388A1 (en) 2000-03-31 2001-10-11 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
WO2002046433A2 (en) * 2000-12-08 2002-06-13 Juan Saus Tnf-inducible promotors and methods for using them
CA2439402A1 (en) 2001-03-02 2002-09-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pcr method
EP1379545A2 (de) 2001-04-19 2004-01-14 Gesellschaft für biotechnologische Forschung mbH (GBF) Verfahren zur herstellung stabiler, regenerierbarer antikörper-arrays
US6812341B1 (en) 2001-05-11 2004-11-02 Ambion, Inc. High efficiency mRNA isolation methods and compositions
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US20030013208A1 (en) 2001-07-13 2003-01-16 Milagen, Inc. Information enhanced antibody arrays
US20040072181A1 (en) * 2002-01-22 2004-04-15 Whitehead Alexander Steven Methods for determining drug responsiveness
US7399643B2 (en) 2002-09-12 2008-07-15 Cyvera Corporation Method and apparatus for aligning microbeads in order to interrogate the same
US20040126875A1 (en) 2002-09-12 2004-07-01 Putnam Martin A. Assay stick
WO2004019277A1 (en) 2002-08-20 2004-03-04 Cyvera Corporation Diffraction grating-based encoded micro-particles for multiplexed experiments
US7190522B2 (en) 2002-09-12 2007-03-13 Cyvera Corporation Chemical synthesis using diffraction grating-based encoded optical elements
US7252976B2 (en) 2002-08-28 2007-08-07 Board Of Regents The University Of Texas System Quantitative RT-PCR to AC133 to diagnose cancer and monitor angiogenic activity in a cell sample
US7482436B2 (en) 2002-08-30 2009-01-27 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human antihuman interleukin-6 antibody and fragment of antibody
US7092160B2 (en) 2002-09-12 2006-08-15 Illumina, Inc. Method of manufacturing of diffraction grating-based optical identification element
CA2499037A1 (en) 2002-09-12 2004-03-25 Cyvera Corporation Method and apparatus for labelling using diffraction grating-based encoded optical identification elements
EP1540591A1 (en) 2002-09-12 2005-06-15 Cyvera Corporation Diffraction grating-based encoded micro-particles for multiplexed experiments
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
JP4685369B2 (ja) * 2004-04-30 2011-05-18 独立行政法人科学技術振興機構 関節リウマチ診断用試薬
US20060008823A1 (en) 2004-05-12 2006-01-12 Kemp Jennifer T DNA profiling and SNP detection utilizing microarrays
TW200630106A (en) * 2004-10-08 2006-09-01 Wyeth Corp Immunotherapy of autoimmune disorders
GB0422417D0 (en) * 2004-10-08 2004-11-10 Ihg Diagnostics Improvements in induced heteroduplex generators
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
JO3058B1 (ar) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
AU2006259583A1 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CN100338228C (zh) * 2005-06-30 2007-09-19 卫生部北京医院 一种预测2型糖尿病易感性的试剂
CA2620082A1 (en) * 2005-08-24 2007-03-01 Genizon Biosciences Inc. Genemap of the human genes associated with crohn's disease
WO2007038501A2 (en) * 2005-09-27 2007-04-05 The Feinstein Institute For Medical Research Rheumatoid arthritis markers
EP1857559A1 (en) * 2006-05-16 2007-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for predicting responsiveness to TNF alpha blocking agents
US20080293582A1 (en) * 2006-08-30 2008-11-27 Xilin Li Markers and Methods for Assessing and Treating Ulcerative Colitis and Related Disorders Using a 43 Gene Panel
WO2008132176A2 (en) * 2007-04-27 2008-11-06 Universite Catholique De Louvain Method for evaluating the response of an individual to tnf blocking therapy

Also Published As

Publication number Publication date
US20100303813A1 (en) 2010-12-02
WO2008154423A2 (en) 2008-12-18
EA017815B1 (ru) 2013-03-29
CN103710458A (zh) 2014-04-09
WO2008154423A3 (en) 2009-02-05
KR20100037590A (ko) 2010-04-09
IL202562A0 (en) 2011-08-01
SG182183A1 (en) 2012-07-30
EP2167687A2 (en) 2010-03-31
AU2008261869A1 (en) 2008-12-18
JP5719591B2 (ja) 2015-05-20
EP2167687B1 (en) 2013-03-27
AU2008261869B2 (en) 2014-12-18
BRPI0812461A2 (pt) 2017-06-13
EP2617837A3 (en) 2013-10-23
MX2009013410A (es) 2010-03-22
ZA200909215B (en) 2010-09-29
CN101796197A (zh) 2010-08-04
CN101796197B (zh) 2014-02-12
NZ581742A (en) 2012-09-28
IL223419A0 (en) 2013-02-03
EA200971131A1 (ru) 2010-06-30
EP2167687A4 (en) 2010-10-13
JP2014033676A (ja) 2014-02-24
JP2010529464A (ja) 2010-08-26
CA2690898A1 (en) 2008-12-18
EP2617837A2 (en) 2013-07-24

Similar Documents

Publication Publication Date Title
NO20093488L (no) Biomarkorer for a predikere anti-TNF respons eller ikke-respons
MX2009009261A (es) Anticuerpos anti-ip-10 y metodos para su uso.
Dealberto Ethnic origin and increased risk for schizophrenia in immigrants to countries of recent and longstanding immigration
WO2009117122A3 (en) Genetic analysis
TW200740844A (en) Novel MAdCAM antibodies
MX2014006158A (es) Metodos para el tratamiento de artritis psoriasica (psa) utilizando antagonistas de il-17 y alelos con respuesta o sin respuesta a la psa.
NO20073882L (no) Human anti-interferon gamma antistoffer og fremgangsmater for anvendelser derav
NO20063197L (no) Mutanter av anti-CD40 antistoff
CR11179A (es) Anticuerpos humanizados contra el globometro ab (20-42) y sus usos
ATE469658T1 (de) Kombinationstherapien gegen multiple toll-like- rezeptoren und ihre verwendung
TW200608961A (en) Methods and reagents for the treatment of metabolic disorders
MX388168B (es) Un anticuerpo anti-amiloide beta (a?) monoclonal humanizado para usarse en el tratamiento de enfermedad de alzheimer.
MY154984A (en) Preventing autoimmune disease
Dunger et al. Can we identify adolescents at high risk for nephropathy before the development of microalbuminuria?
PL1631312T3 (pl) Kompozycje i sposoby terapii choroby zapalenia jelit
ATE549638T1 (de) 13c-mr-bildgebung oder spektroskopie von zelltod
TW200716172A (en) Pharmaceutical compositions for treating lower motor neuron diseases
Coresh et al. A stable definition of chronic kidney disease improves knowledge and patient care
WO2008048902A8 (en) Methods of using single nucleotide polymorphisms in the il23r gene to predict or diagnose inflammatory bowel disease
HK1142929A (en) Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
American Occupational Therapy Association AOTA’s societal statement on livable communities
Stern The intervention of private entities and states as “friends of the court” in WTO dispute settlement proceedings
Brunetti et al. P232 Endogenous serum immunoglobulin levels in hospitalized patients
WO2006108094A3 (en) Organ homing genes of cancer metastases
Zhang et al. P043 HLA-DP donor specific antibodies associated with antibody mediated rejection and poor allograft survival following lung transplant

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application